Objective: To construct an evaluation index system of cervical cancer prevention and control literacy, so as to provide an assessment tool for cervical cancer prevention and control literacy. Methods: The preliminary framework for cervical cancer prevention and control literacy was designed based on literature review. Twenty-one experts with both theoretical and practical experience in cervical cancer prevention and control were invited to participate in two rounds of Delphi consultation. The weights of indicators were determined by the percentage weighting method and product method, and the response rate, authority level, opinion concentration degree, and coordination degree of experts were evaluated. Results: Twenty-one experts participated in the consultation, including 3 males and 18 females. There were 11 experts with a doctor's degree, 7 with a master's degree and 3 with a bachelor's degree. All of them had senior professional titles and had more than 10 years of working experience. The recovery rates of the two rounds of consultations were 100.00% and 95.24%, the authority coefficients were 0.963 and 0.948, and Kendall's coefficients of concordance were 0.175 and 0.148 (both P<0.05), respectively. The final cervical cancer prevention and control literacy evaluation index system included 3 primary indicators (basic knowledge and concepts: 0.334; healthy lifestyle and behaviors: 0.338; basic skills: 0.328), 12 secondary indicators, with "capability to accurately acquire, comprehend, evaluate and apply health information" having the highest weight (0.166), and 51 tertiary indicators, with "HPV vaccination" (0.086), "consulting on relevant issues" (0.082), and "expressing personal perspectives" (0.080) having relatively higher weights. Conclusion The evaluation index system of cervical cancer prevention and control literacy serves as a valid assessment tool for women of appropriate age, providing the reference for developing targeted health education to enhance cervical cancer prevention and control literacy.

Objective To preliminarily analyze the genotypic and phenotypic characteristics of glucose-6-phosphate dehydrogenase(G6PD)in blood donors and recipients in Dongguan region,as well as the impact of these characteristics on the efficacy of blood transfusion therapy.Methods A total of 351 pairs of blood sam-ples from donors and recipients were collected from the Tenth Affiliated Hospital of Southern Medical Uni-versity/Dongguan People's Hospital between May and November in 2023.These samples were tested for G6PD genotype,G6PD enzyme activity,erythrocyte osmotic fragility,and blood routine parameters.Addition-ally,hemoglobin levels before and after blood transfusion were collected from recipients for statistical analy-sis.Results The carrier rates of G6PD mutant genes among donors and recipients in Dongguan region were 6.84％and 5.83％,respectively.Six mutation sites were identified,with c.1388G＞A,c.1376G＞T,and c.95A＞G accounting for 84.09％of all mutations.A negative correlation was observed between G6PD activi-ty and blood storage duration in wild-type donors.The G6PD activity significantly decreased when blood from healthy donors was transfused into recipients through standard procedures.Recipients carrying c.1388G＞A,c.1376G＞T,c.95A＞G,c.871G＞A,c.1024C＞T mutation sites showed no statistically significant difference in hemoglobin increment after receiving blood from donors carrying c.1388G＞A,c.1376G＞T,c.95A＞G,c.871G＞A,c.1376G＞T/c.1360C＞T,or c.1388G＞A/c.95A＞G mutation sites.In the internal medicine re-strictive transfusion group,recipients who received blood with enzyme activity≥1300 U/L demonstrated a significantly greater increase in hemoglobin levels compared to those transfused with blood with enzyme activ-ity＜1 300 U/L(P=0.042).Conclusion The carrier rates of G6PD mutant genes among donors and recipi-ents in Dongguan region are both above 5.00％,indicating a relatively high carriage rate.The three primary mutation sites,c.1388G＞A,c.1376G＞T,and c.95A＞G,account for over 80.00％of all mutations.No ad-verse effects on treatment efficacy are observed in recipients carrying G6PD mutant genes after receiving blood from donors with G6PD mutant genes.However,in restrictive transfusion practices within internal medicine,recipients receiving blood with low G6PD enzyme activity demonstrate a reduced hemoglobin increase per unit compared to those receiving blood with normal G6PD enzyme activity.

Aim To explore the mechanisms of PM2.5 exposure exacerbating bleomycin(BLM)-induced idio-pathic pulmonary fibrosis(IFP)by regulating ferropto-sis via nuclear factor 2 related factor 2(Nrf2)/solute carrier family 7 member 11(SLC7A11)/glutathione peroxidase(GPX)4 axis.Methods Forty C57BL/6J mice were randomized into the control,BLM,PM2.5,BLM+PM2.5 and sulforaphane(SFN,Nrf2 agonist)groups,with eight mice in each group.PM2.5 expo-sures were conducted to the BLM-induced IPF mice for two weeks.The lung function was measured,and the content of hydroxyproline(HYP)in lung tissue and the pathomorphology of lungs were observed.Reactive oxygen species(ROS),malondialdehyde(MDA),ferrous ion(Fe2+)and glutathione(GSH)of the lung tissue were measured by ELISA.The mRNA and pro-teins levels of Nrf2,SLC7A11,GPX4,collagen typeⅠ(COL-1),α-smooth muscle actin(α-SMA)were measured by quantitative polymerase chain reaction(qPCR)and Western blot.Results Compared with the control group,the lung function of mice was signif-icantly reduced(P＜0.01)in the BLM and PM2.5 groups,while lung tissue showed the characteristic pathological changes of pulmonary fibrosis such as a large number of inflammatory cell infiltration,alveolar wall fracture,thickening,collagen deposition,and sig-nificantly increased HYP,Fe2+,ROS,MDA(P＜0.05,P＜0.01),genes and proteins of COL-1,α-SMA(P＜0.01);and decreased GSH,Nrf2,SLC7A11,GPX4 genes and proteins(P＜0.05,P＜0.01).The above-mentioned lesions were markedly aggravated in the BLM+PM2.5 group compared with the BLM(P＜0.05)and PM2.5 groups(P＜0.01),and were also improved in the SFN group(P＜0.05,P＜0.01).Conclusions PM2.5 exposures can exac-erbate IPF-induced IPF in mice,and the regulating of Nrf2/SLC7 A1 1/GPX4 axis and ferroptosis might be in-volved in the related mechanisms.

Aim To explore the mechanisms of PM2.5 exposure exacerbating bleomycin(BLM)-induced idio-pathic pulmonary fibrosis(IFP)by regulating ferropto-sis via nuclear factor 2 related factor 2(Nrf2)/solute carrier family 7 member 11(SLC7A11)/glutathione peroxidase(GPX)4 axis.Methods Forty C57BL/6J mice were randomized into the control,BLM,PM2.5,BLM+PM2.5 and sulforaphane(SFN,Nrf2 agonist)groups,with eight mice in each group.PM2.5 expo-sures were conducted to the BLM-induced IPF mice for two weeks.The lung function was measured,and the content of hydroxyproline(HYP)in lung tissue and the pathomorphology of lungs were observed.Reactive oxygen species(ROS),malondialdehyde(MDA),ferrous ion(Fe2+)and glutathione(GSH)of the lung tissue were measured by ELISA.The mRNA and pro-teins levels of Nrf2,SLC7A11,GPX4,collagen typeⅠ(COL-1),α-smooth muscle actin(α-SMA)were measured by quantitative polymerase chain reaction(qPCR)and Western blot.Results Compared with the control group,the lung function of mice was signif-icantly reduced(P＜0.01)in the BLM and PM2.5 groups,while lung tissue showed the characteristic pathological changes of pulmonary fibrosis such as a large number of inflammatory cell infiltration,alveolar wall fracture,thickening,collagen deposition,and sig-nificantly increased HYP,Fe2+,ROS,MDA(P＜0.05,P＜0.01),genes and proteins of COL-1,α-SMA(P＜0.01);and decreased GSH,Nrf2,SLC7A11,GPX4 genes and proteins(P＜0.05,P＜0.01).The above-mentioned lesions were markedly aggravated in the BLM+PM2.5 group compared with the BLM(P＜0.05)and PM2.5 groups(P＜0.01),and were also improved in the SFN group(P＜0.05,P＜0.01).Conclusions PM2.5 exposures can exac-erbate IPF-induced IPF in mice,and the regulating of Nrf2/SLC7 A1 1/GPX4 axis and ferroptosis might be in-volved in the related mechanisms.

Objective To explore the the correlation between cystatin C(Cys C),beta-2 microglobulin(β2-MG)and ischemic cerebral small vessel disease(CSVD)and its subgroups.Methods Totally 234 patients with CSVD were assigned to the study group,and 92 elderly people with no abnormal findings in head MRI were selected as controls.The CSVD patients were further divided into the subgroups of lacunar infarction(LI),white matter lesion(WML)and LI+WML.Each group was compared risk factors include the blood level of Cys C and β2-MG.Results There were statistically significant differences between CSVD group and control group in cystatin C(Cys C)and β2-MG(P<0.05).Cystatin C(Cys C)and β2-MG there were statistically significant differences between WML group and control group(P<0.05),and also between WML+LI group and control group(P<0.05).Logistic regression analysis and comparison across subgroups showed Cys C and β2-MG to be the common risk factors for WML group and WML+LI group inpatients with ischemic cerebral small vessel disease.Conclusion Cys C and β2-MG are the common risk factors for WML group and WML+LI group inpatients with ischemic cerebral small vessel disease.The risk factors vary across different CSVD subgroups.

The steroid constituents in the 75% ethanol extract of Cyanotis arachnoidea and their anti-HSV-1 activities in vitro were investigated in this study. The ethyl acetate fraction of the extract was isolated and purified using silica gel, ODS, Sephadex LH-20 column chromatography, and semi-preparative HPLC. Structural identification was conducted based on spectroscopic data. Ten steroid compounds were isolated and identified, namely makisterone A 3-acetate(1), makisterone A 2-acetate(2), makisterone A(3), ajugasterone C 2-acetate(4), ajugasterone C(5), 20-hydroxyecdysone 2-acetate(6), 20-hydroxyecdysone 3-acetate(7), podecdysone C(8), rubrosterone(9), and poststerone(10). Compounds 1 and 2 are new steroid compounds. The anti-HSV-1 activities of compounds 1-10 were evaluated using the CPE inhibition method. Vero cells were used in the experiment, with acyclovir as the positive control. The results showed that compounds 9 and 10 showed anti-HSV-1 activity, with EC_(50) values of 83.11 and 103.62 μg·mL~(-1), respectively.
Herpesvirus 1, Human/drug effects* ; Antiviral Agents/isolation & purification* ; Animals ; Chlorocebus aethiops ; Steroids/isolation & purification* ; Vero Cells ; Drugs, Chinese Herbal/isolation & purification* ; Molecular Structure

Objective To analyze the clinical efficacy of Saccharomyces boulardii capsules combined with mesalazine enteric-coated in the treatment of patients with ulcerative colitis(UC)and its influence on intestinal microecology and mucosal inflammation.Methods Patients with UC were randomly divided into control group and treatment group.The control group took mesalazine enteric-coated(0.5 g,tid),while the treatment group was given Saccharomyces boulardii capsule orally(0.5 g,bid)on the basis of the control group,and both groups were treated for 2 months.The clinical efficacy,mucosal healing status(modified Mayo score,Geboes index score),intestinal mucosal inflammatory indicators and intestinal microecology were compared between groups of patients,and the safety evaluation was performed.Results 45 cases were included in control group and treatment group,respectively.After 2 months of treatment,the total effective rates of treatment in treatment group and control group were 86.67％(39 cases/45 cases)and 66.67％(30 cases/45 cases),the difference was statistically significant(P＜0.05).After treatment,the modified Mayo scores were(3.02±0.85)and(3.88±1.01)points,the Geboes index scores were(0.63±0.15)and(0.91±0.20)points,the levels of interleukin-6(IL-6)were(39.27±8.89)and(67.94±11.02)pg·mL-1,the levels of interleukin-10(IL-10)were(61.44±7.76)and(50.28±6.74)ng·L-1,the levels of interleukin-23(IL-23)were(452.19±80.01)and(514.68±95.93)ng·mL-1,the levels of tumor necrosis factor-α(TNF-α)were(30.93±4.68)and(46.75±8.31)ng·L-1,the Bifidobacteria counts were(10.49±1.87)and(9.57±1.73)lgCFU·g-1,the Lactobacillus counts were(9.43±1.66)and(7.94±1.39)lgCFU·g-1,the Colibacillus counts were(7.15±1.29)and(8.03±1.47)lgCFU·g-1,the Enterococci counts were(6.59±1.02)and(7.81±1.14)lgCFU·g-1,respectively(all P＜0.05).The adverse reactions in treatment group included nausea,the adverse drug reactions in control group included nausea and dizziness.The incidence rates of adverse drug reactions in treatment group and control group were 4.44％(2 cases/45 cases)and 4.44％(2 cases/45 cases),respectively(P＞0.05).Conclusion Saccharomyces boulardii capsule combined with mesalazine enteric-coated tablet has significant effect in the treatment of UC,which can effectively inhibit the intestinal mucosal inflammation,improve the intestinal microecology and promote the intestinal mucosal healing,and it has good safety.

Objective To analyze the clinical efficacy of Saccharomyces boulardii capsules combined with mesalazine enteric-coated in the treatment of patients with ulcerative colitis(UC)and its influence on intestinal microecology and mucosal inflammation.Methods Patients with UC were randomly divided into control group and treatment group.The control group took mesalazine enteric-coated(0.5 g,tid),while the treatment group was given Saccharomyces boulardii capsule orally(0.5 g,bid)on the basis of the control group,and both groups were treated for 2 months.The clinical efficacy,mucosal healing status(modified Mayo score,Geboes index score),intestinal mucosal inflammatory indicators and intestinal microecology were compared between groups of patients,and the safety evaluation was performed.Results 45 cases were included in control group and treatment group,respectively.After 2 months of treatment,the total effective rates of treatment in treatment group and control group were 86.67％(39 cases/45 cases)and 66.67％(30 cases/45 cases),the difference was statistically significant(P＜0.05).After treatment,the modified Mayo scores were(3.02±0.85)and(3.88±1.01)points,the Geboes index scores were(0.63±0.15)and(0.91±0.20)points,the levels of interleukin-6(IL-6)were(39.27±8.89)and(67.94±11.02)pg·mL-1,the levels of interleukin-10(IL-10)were(61.44±7.76)and(50.28±6.74)ng·L-1,the levels of interleukin-23(IL-23)were(452.19±80.01)and(514.68±95.93)ng·mL-1,the levels of tumor necrosis factor-α(TNF-α)were(30.93±4.68)and(46.75±8.31)ng·L-1,the Bifidobacteria counts were(10.49±1.87)and(9.57±1.73)lgCFU·g-1,the Lactobacillus counts were(9.43±1.66)and(7.94±1.39)lgCFU·g-1,the Colibacillus counts were(7.15±1.29)and(8.03±1.47)lgCFU·g-1,the Enterococci counts were(6.59±1.02)and(7.81±1.14)lgCFU·g-1,respectively(all P＜0.05).The adverse reactions in treatment group included nausea,the adverse drug reactions in control group included nausea and dizziness.The incidence rates of adverse drug reactions in treatment group and control group were 4.44％(2 cases/45 cases)and 4.44％(2 cases/45 cases),respectively(P＞0.05).Conclusion Saccharomyces boulardii capsule combined with mesalazine enteric-coated tablet has significant effect in the treatment of UC,which can effectively inhibit the intestinal mucosal inflammation,improve the intestinal microecology and promote the intestinal mucosal healing,and it has good safety.

Humans ; Osteoma, Osteoid/surgery* ; Bone Neoplasms/surgery* ; Tomography, X-Ray Computed